Department of Gynecologic Oncology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Department of Anatomic Pathology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Int J Gynecol Cancer. 2024 Oct 7;34(10):1556-1560. doi: 10.1136/ijgc-2024-005778.
Isolated positive para-aortic lymph node metastasis in endometrial cancer is an uncommon event, ranging from 1% to 3%.
Our aim was to evaluate the impact of sentinel lymph node (SLN) mapping on the risk of isolated positive para-aortic lymph node metastasis.
We retrospectively evaluated a series of 426 patients who underwent SLN mapping with at least one SLN detected from January 2013 to December 2021 (SLN group) compared with a historical series of 209 cases who underwent a systematic pelvic and para-aortic lymphadenectomy between June 2007 and April 2015 (LND group). Isolated para-aortic lymph node metastasis recurrences were included in the SLN group analysis.
In the SLN group, 168 cases (39.4%) had backup systematic lymphadenectomy, and 56 (13.1%) had positive lymph nodes compared with 34 (16.3%) in LND group (p=0.18). The SLN group had higher rates of minimally invasive surgeries (p<0.001) and presence of lymphovascular space invasion (p<0.001). Moreover, SLN group had fewer other uterine risk factors, such as high-grade tumors (p<0.001), and deep myometrial invasion (p<0.001). We found that SLN mapped outside the pelvis at pre-sacral, common iliac areas, and para-aortic regions in 2.8% (n=12), 11.5% (n=49), and 1.6% (n=7) of cases, respectively. Overall, 52 (12.2%) patients had positive SLNs, and 3 (5.7%) positive SLNs were found outside the pelvis-one in the pre-sacral region, one in the common iliac area, and one in the para-aortic region. An isolated para-aortic lymph node was found in only 2 (0.5%) cases in the SLN group compared with 7 (3.3%) cases in the LND group (p=0.004).
SLN protocol accurately predicts lymph node status and may decrease the risk of failed identification of isolated para-aortic lymph node metastasis compared with systematic lymphadenectomy.
子宫内膜癌中孤立性腹主动脉旁淋巴结转移较为少见,占比为 1%至 3%。
本研究旨在评估前哨淋巴结(SLN)检测对孤立性腹主动脉旁淋巴结转移风险的影响。
回顾性分析了 2013 年 1 月至 2021 年 12 月期间 426 例接受 SLN 检测且至少检测到 1 枚 SLN 的患者(SLN 组),并与 2007 年 6 月至 2015 年 4 月期间接受系统盆腔和腹主动脉旁淋巴结清扫术的 209 例患者(LND 组)进行比较。SLN 组的孤立性腹主动脉旁淋巴结转移复发患者纳入分析。
在 SLN 组中,168 例(39.4%)患者行辅助系统淋巴结清扫术,56 例(13.1%)患者的淋巴结为阳性,而 LND 组中 34 例(16.3%)患者的淋巴结为阳性(p=0.18)。SLN 组微创手术的比例较高(p<0.001),且存在脉管间隙浸润的比例较高(p<0.001)。此外,SLN 组的其他子宫危险因素较少,如高级别肿瘤(p<0.001)和深肌层浸润(p<0.001)。我们发现,2.8%(n=12)、11.5%(n=49)和 1.6%(n=7)的患者的 SLN 在骶前、髂总及腹主动脉旁区域外被检出,分别有 2.8%(n=12)、11.5%(n=49)和 1.6%(n=7)的患者的 SLN 在骶前、髂总及腹主动脉旁区域外被检出。总体而言,52 例(12.2%)患者的 SLN 为阳性,其中 3 例(5.7%)阳性 SLN 位于盆腔外,1 例位于骶前区域,1 例位于髂总区域,1 例位于腹主动脉旁区域。与 LND 组 7 例(3.3%)相比,SLN 组仅发现 2 例(0.5%)孤立性腹主动脉旁淋巴结转移(p=0.004)。
与系统淋巴结清扫术相比,SLN 方案能更准确地预测淋巴结状态,降低孤立性腹主动脉旁淋巴结转移漏诊的风险。